These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36238308)

  • 1. Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors.
    Asano Y; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Higuchi T; Taniguchi Y; Morinaga S; Horimoto T; Nakai M; Kadono Y; Nojima T; Tsuchiya H
    Front Immunol; 2022; 13():980456. PubMed ID: 36238308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
    Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
    World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
    J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report.
    Iribe Y; Furuya M; Shibata Y; Yasui M; Funahashi M; Ota J; Iwashita H; Nagashima Y; Hasumi H; Hayashi N; Makiyama K; Kondo K; Tanaka R; Yao M; Nakaigawa N
    Fam Cancer; 2021 Jan; 20(1):75-80. PubMed ID: 32666341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of immune checkpoint inhibitors in the treatment of kidney cancer oral metastasis. A case report.
    Bruckmann M; Brenet E; Boulagnon-Rombi C; Louvrier A; Mauprivez C
    J Stomatol Oral Maxillofac Surg; 2024 Oct; 125(5S2):101913. PubMed ID: 38719194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
    Pignot G; Thiery-Vuillemin A; Albigès L; Walz J; Lang H; Balssa L; Parier B; Geoffrois L; Bensalah K; Schlürmann F; Ladoire S; Bigot P; Borchiellini D; Cassuto O; Thibault C; Ingels A; Saldana V; Roubaud G; Bernhard JC; Gravis G; Barthélémy P
    Eur Urol Oncol; 2022 Oct; 5(5):577-584. PubMed ID: 35853818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.
    Singla N; Elias R; Ghandour RA; Freifeld Y; Bowman IA; Rapoport L; Enikeev M; Lohrey J; Woldu SL; Gahan JC; Bagrodia A; Brugarolas J; Hammers HJ; Margulis V
    Urol Oncol; 2019 Dec; 37(12):924-931. PubMed ID: 31522865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response rate specific to bone metastasis of various cancers for immune checkpoint inhibitors: a systematic review.
    Tsukamoto S; Mavrogenis AF; Masunaga T; Aiba H; Aso A; Honoki K; Fujii H; Kido A; Tanaka Y; Tanaka Y; Errani C
    Eur J Orthop Surg Traumatol; 2024 Aug; 34(6):2823-2833. PubMed ID: 38836904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors.
    Adhikari A; Sapkota S; Gogia S; Kc O
    Cancer Epidemiol; 2024 Oct; 92():102639. PubMed ID: 39146874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
    Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
    J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [DEFERRED NEPHRECTOMY IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA AFTER A NEAR-COMPLETE RESPONSE TO IMMUNOTHERAPY].
    Purim O; Raz O; Eisner A; Baram N; Leonov Polak M; Rybo L
    Harefuah; 2022 Dec; 161(12):763-768. PubMed ID: 36916116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-specific Response to Nivolumab in Renal Cell Carcinoma.
    Negishi T; Furubayashi N; Nakagawa T; Nishiyama N; Kitamura H; Hori Y; Kuroiwa K; Son Y; Seki N; Tomoda T; Okajima E; Nakamura M
    Anticancer Res; 2021 Mar; 41(3):1539-1545. PubMed ID: 33788747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review.
    Ghoreifi A; Vaishampayan U; Yin M; Psutka SP; Djaladat H
    JAMA Oncol; 2024 Feb; 10(2):240-248. PubMed ID: 38095885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.
    Nemoto Y; Ishihara H; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
    Int Urol Nephrol; 2022 Jan; 54(1):47-54. PubMed ID: 34704214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
    Nada A; Bhat R; Cousins J
    Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
    Zarrabi K; Wu S
    Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuation of immune checkpoint inhibitors for newly developed brain metastasis during immune checkpoint inhibitor treatment for oligoprogressive metastatic renal cell carcinoma.
    Ishihara H; Fukuda H; Yoshida K; Hashimoto Y; Kondo T; Takagi T
    Int J Urol; 2023 Feb; 30(2):240-242. PubMed ID: 36397731
    [No Abstract]   [Full Text] [Related]  

  • 20. Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib.
    Iacovelli R; Ciccarese C; Maruzzo M; Atzori F; Galli L; Scagliarini S; Massari F; Verzoni E; Cannella A; Maratta MG; Caserta C; Bimbatti D; Deppieri FM; Dessi M; Paolieri F; Riccardi F; Bracarda S; De Giorgi U; Basso U; Tortora G; Procopio G
    Clin Genitourin Cancer; 2022 Oct; 20(5):498.e1-498.e9. PubMed ID: 35768316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.